Disclosed is a system for determining fecundity of an embryo utilizing a non¬ invasive grading of early stage embryos (pre-hatching) based upon specific gravity, density and/or estimated weight. The system allows 100% recovery of embryos and can detect differences in growth potential at the earliest stages of development. The system may further enhance the development of embryos by utilization of microfluidic effects during use. The disclosed system supports a wide variety of scenarios for human and animal reproductive technologies and related products and services.

The present disclosure relates to a method for producing mesenchymal stem cells from pluripotent stem cells and mesenchymal stem cells prepared by the method. The present disclosure enables mesenchymal stem cells having superior proliferation rate while having superior intrinsic biological activity to be obtained with high yield by sequentially performing three-dimensional suspension culture using pluripotent stem cells, particularly induced pluripotent stem cells (iPSCs), as starting cells and adherent culture of cell aggregates formed therethrough. The mesenchymal stem cells produced by the method of the present disclosure can be usefully used in compositions for treating bone diseases, cartilage diseases or inflammatory and autoimmune diseases owing to high differentiation efficiency into bone and cartilage and superior anti-inflammatory activity.

This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.

A method, apparatus, and system are provided for the printing and maturation of living tissue in an Earth-referenced reduced gravity environment such as that found on a spacecraft or on other celestial bodies. The printing may be three-dimensional structures. The printed structures may be manufactured from low viscosity biomaterials.

A cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135-45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g. In an embodiment, the device is used as a point-of-care and/or portable device. Further, the present disclosure describes software that, when executed by a processor, causes the device to perform the disclosed functions.

By swinging a culture vessel before aspiration removal of a medium, a centrally dense state (83) of the cell population is formed. In the centrally dense state (83), a cell cluster (84) is separated from an outlet port (58a). After aspiration removal of the medium, a new medium is introduced into the culture vessel. After the introduction of the new medium, an overall dispersed state of the cell population is formed.

Disclosed is a system for determining fecundity of an embryo utilizing a non¬invasive grading of early stage embryos (pre-hatching) based upon specific gravity, density and/or estimated weight. The system allows 100% recovery of embryos and can detect differences in growth potential at the earliest stages of development. The system may further enhance the development of embryos by utilization of microfluidic effects during use. The disclosed system supports a wide variety of scenarios for human and animal reproductive technologies and related products and services.

The invention provides universally acceptable “off-the-shelf” hypoimmune pluripotent (HIP) cells and hypoimmune chimeric antigen receptor T (CAR-T) cells derived from the HIP cells. The engineered therapeutic cells can be administered to subjects as an adoptive cell-based immunotherapy to treat cancer.

Current invention relates to biotechnology sphere and particularly describes the novel approach for non-attached biofilm-like aggregates fabrication in vitro under artificial microgravity environment conditions. Non-attached aggregates are grown under magnetic levitation conditions achieved by placing microorganisms suspension in paramagnetic nutrient medium in inhomogeneous magnetic field created by specifically developed permanent magnets. The invention method can produce biofilm-like aggregates from protozoa, fungi, microalgae, Gram-positive or Gram-negative bacteria and/or a consortium. The presented technology can be used for development of medications for treatment of chronic infections, antiseptics and solutions for surfaces, as well as in other applications requiring the use of non-attached biofilm-like aggregates model.

The invention refers to a method for culturing cells in a substrate in which a chamber having at least one side wall, a bottom, and a top is formed, comprising introduction of cells into the chamber, tilting of the substrate such that the cells accumulate on a side wall of the chamber, and holding the substrate in the tilted orientation such that the cells form a three-dimensional cell aggregate.